期刊文献+

循环肿瘤细胞临床应用的新进展 被引量:3

Advances in research on circulating tumor cells
下载PDF
导出
摘要 循环肿瘤细胞(Circulating tumor cells,CTCs)是指释放到血液中的罕见肿瘤细胞,被认为是肿瘤血液转移的关键步骤之一。循环肿瘤细胞的检测对于肿瘤的诊断、治疗和预后判定都具有非常重要的意义,是目前肿瘤研究的热点之一。本文将从预测生物标志物、治疗反应、预后、血浆肿瘤DNA四个方面介绍循环肿瘤细胞临床应用的最新研究进展。 Circulating tumor cells (CTCs)are defined as cells that have detached,spontaneously or as a result of clinical operations,from a primary tumor or its metastatic lesions and circulate in the peripheral blood.They are considered as the primary reason for postoperative recurrence and distant metastasis of malignant tumors.CTCs have a advantage in cancers diagnosis,treatment and prognosis.This articlere views recent circulating tumor cells advances in research on diagnoses,response to treatment,prognosis and plasma tumor DNA.
出处 《现代肿瘤医学》 CAS 2014年第11期2746-2748,共3页 Journal of Modern Oncology
基金 国家自然科学基金资助项目(编号:81060177) 云南省应用基础研究基金项目(编号:2012FB067) 云南省卫生科技基金项目(编号:2012WS041 2010NS079)
关键词 循环肿瘤细胞 诊断 治疗反应 预后 血浆肿瘤DNA circulating tumor cells diagnoses treatment response prognosis plasma tumor DNA
  • 相关文献

参考文献26

  • 1Hanahan D, Weinberg RA. Hallmarks of cancer : The next genera- tion[J]. Cell,2011,144(5) :646 -674.
  • 2Ashworth TR. A ease of cancer in which cells similar to those in the turnouts were seen in the blood after death[ J]. Aust Med J, 1869, 14(32) :146 - 149.
  • 3Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial -mesenehymal transition [ J]. Nat Rev Mol Cell Biol, 2014, 15 (3) :178 -196.
  • 4Balie M, Lin H, Williams A, et al. Progress in circulating tumor cell capture and analysis : Implications for cancer management [ J ]. Ex- pert Rev Mol Diagn ,2012,12 ( 3 ) :303 - 312.
  • 5Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare eireu- lating tumor cells in cancer patients by mieor- el'lip teehnolgy[J]. Nature, 2007,450 ( 7173 ) : 1235 - 1239.
  • 6Theodoropoulos PA, Polioudaki H, Agelakis, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of pa- tients with breast cancer[ J]. Cancer Lett,2010,288 ( 1 ) :9 - 16.
  • 7Mehes G, Witt A, Kubista E, et al. Circulating breast cancer cells are frequently apoptotie [ J]. Am J Patho1,2001,159 (1) : 17 - 20.
  • 8Ligthart ST, Coumans FA, Bidard FC, et al. Circulating tumor eeUs count and morphological features in breast, eoloreetal and prostate cancer [ J ]. PLoS One,2013,8 (6) :6714 - 6718.
  • 9Ran R, Li L, Wang M, et al. Determination of EGFR mutations in single cells mierodissected from enriched lung tumor cells in pe- ripheral blood [ J ]. Anal Bioanal Chem, 2013,405 ( 23 ) : 7377 - 7382.
  • 10Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK - pos- itive non - small - cell lung cancer [ J ]. J Clin Oncol, 2013,31 (18) :2273 -2281.

同被引文献29

  • 1Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines onProstate Cancer. Part 1: Screening, Diagnosis, and Treatment ofClinically Localised Disease[J]. Eur Urol, 2011, 59(1): 61-7.
  • 2Ashwoah TR. A case of cancer in which cells similar to those inthe tumors were seen in the blood after death[J]. Aust Med J,18 69, 14: 146-9.
  • 3Joosse SA, Pantel K. Biologic challenges in the detection ofcirculating tumor cells[J]. Cancer Res, 2013, 73(1): 8-11.
  • 4Wells GA, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomised studies in metaanalyses[EB/OL]. [2013-11-26]. http://www.ohri.ca/programs/clinical epidemiology/oxford.asp.
  • 5Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell countsare prognostic of overall survival in SWOG S0421: a phase iii trialof docetaxel with or without atrasentan for metastatic castrationresistantprostate cancer[J]. J Clin Oncol, 2014, 32(11): 1136-42.
  • 6Thalgott M, Rack B, Eiber M, et al. Categorical versus continuouscirculating tumor cell enumeration as early surrogate markerfor therapy response and prognosis during docetaxel therapy inmetastatic prostate cancer patients[J]. BMC Cancer, 2015, 15: 458.
  • 7Olmos D, Arkenau HT, Ang JE, et al. Circulating tumourcell(CTC) counts as intermediate end points in castration-resistantprostate cancer(CRPC): a single-centre experience[J]. Ann Oncol,2009, 20(1): 27-33.
  • 8Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara, et al.Association of circulating tumor cells with tumor-relatedmethylated DNA in patients with hormone-refractory prostatecancer[J]. Int J Urol, 2010, 17(15): 466-75.
  • 9Resel Folkersma L, San José Manso L, Galante Romo I, et al.Prognostic significance of circulating tumor cell count in patientswith metastatic hormone-sensitive prostate cancer[J]. Urology,2012, 80(6): 1328-32.
  • 10Marín-Aguilera M, Reig ò, lozano JJ, et al. Molecular profiling ofperipheral blood is associated with circulating tumor cells contentand poor survival in metastatic castration-resistant prostatecancer[J]. Oncotarget, 2015, 6(12): 10604-16.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部